摘要
目的观察缬沙坦联合福辛普利治疗IgA肾病蛋白尿的疗效及安全性。方法选择IgA肾病患者60例,随机分成治疗组32例和对照组28例。治疗组给予缬沙坦联合福辛普利治疗;对照组单用福辛普利治疗。疗程为6个月,观察治疗前后24 h尿蛋白定量及药物不良反应情况。结果治疗后治疗组24 h蛋白尿改善显著优于对照组(P<0.01);治疗组总有效率显著高于对照组(P<0.01);两组患者用药后不良反应发生率无显著差异(P>0.05)。结论缬沙坦联合福辛普利治疗IgA肾病蛋白尿疗效显著优于单用福辛普利,且不良反应并无增加。
Objective To observe on the therapeutic effect and safty of Valsartan combined Fosinopril in treating IgA Nephropathy. Methods 60 cases of patients with IgA nephropathy were randomly divided into treatment group 32 cases and control group 28cases. The treatment group was treated with valsartan combined and fosinopril ; the eontrol group treated with fosinopril alone. Course of treatment is 6 months,to observe the urinary protein of 24 h and the situation of adverse drug reactions before and after treatment. Results After treatment, the 24 h proteinuria of treatment group improved significantly better than that of the control group （ P 〈0. 01 ） ; the total effective rate of the treatment group was significantly higher than that of the eontrol group （ P 〈 0. 01 ） ; two groups of patients the incidence of adverse reactions after treatment had no significant difference （ P 〉 0.05 ）. Conclusion The effeet of valsartan combined fosinopril treatment of IgA nephropathy was significantly better than proteinuria alone fosinopril, and no increase in adverse reactions.
出处
《中国医学创新》
CAS
2010年第2期19-20,共2页
Medical Innovation of China
